drugset / Trial / NCT05272696
Pembrolizumab and Induction Chemotherapy in Locally Advanced HNSCC
NaSingle-groupOpen-labelTreatment
Summary
To study induction therapy with Nab-paclitaxel, Cisplatin and Pembrolizumab in patients with Locally Advanced HNSCC.
Timeline
- Start
- 2022-03-01
- Primary completion
- 2026-01-01
- Completion
- 2026-01-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cisplatin | Other / unclassified | 75 mg/m2 | Intravenous |
| Subject | Nab-paclitaxel | Small molecule | 260 mg/m2 | Intravenous |
| Subject | Pembrolizumab | Monoclonal antibody | 200 mg | Intravenous |